Phenex AG benefits from Prof. Wetzel´s longstanding experience in research and early
Ludwigshafen, Germany, April 8th, 2009
“We are delighted that Prof. Wetzel gives us the honour to support our Supervisory Board and us with all his scientific expertise and longstanding experience”
– Dr. Claus Kremoser –
CEO of Phenex
Phenex Pharmaceuticals AG today announced that Prof. Dr. Bernd Wetzel will become the Head of its newly established Scientific Advisory Board. In this function, Prof. Dr. Wetzel will advise Phenex´ operative scientists and evaluate their research results on behalf of the Supervisory Board. Prof. Dr. Wetzel has over 30 years experience in leading positions in the pharmaceutical industry, finally as Director of Research and Preclinical Development at Boehringer Ingelheim. He is Honorary Professor at the Department of Chemistry at the LudwigMaximilians-Universität in Munich and acts as Senior Scientific Advisor and member of the Board on several companies.
“We are delighted that Prof. Wetzel gives us the honour to support our Supervisory Board and us with all his scientific expertise and longstanding experience”, welcome Dr. Claus Kremoser, CEO and Thomas Hoffmann, CFO the new Head of Phenex´ SAB. “In Prof. Wetzel we have found the ideal person to guide and support our preclinical and early clinical development program of our FXR agonist in Type 2 Diabetes.”
“We cordially welcome Prof. Dr. Wetzel as Head of the Scientific Advisory Board and direct Scientific Advisor to Phenex´ Supervisory Board”, complements Dr. Farsin Yadegardjam, Partner at EVP Capital Management AG and Head of Phenex´ Supervisory Board. “His outstanding industry experience as well as his work as advisor to other Venture Capital firms demonstrates that he can contribute significant value at this interface position between R&D and commercialisation.”
Waldhofer Str. 104
Phone: +49 6221 65282-0
Fax: +49 6221 65282-10
Dr. Claus Kremoser
About Phenex Pharmaceuticals AG
Phenex is a privately held drug discovery and development company headquartered in Heidelberg. The biopharmaceutical company can now build on nineteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex´s R&D activities are centered around diseases of liver such as NASH and cancer.